Aktienanalyse zu TScan Therapeutics Inc (TCRX)TCRXTScan Therapeutics Inc

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

TScan Therapeutics Inc (TCRX) is currently trading at $0.75, which is significantly lower than the analyst price target of $5, indicating potential upside. However, the stock has a low Relative Strength Index (RSI) of 38.43, suggesting it is nearing oversold conditions, but it has also seen a 56.94% decline over the past year, indicating ongoing challenges. The company reported a Q2 2026 revenue of $1.1 million, down from $3.1 million in Q2 2025, reflecting weak market demand. The main risk is the negative net income of -$30.36 million in Q2 2026, which highlights profitability concerns.